Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 91-99

  Rebello, Sam S ^a   Blank, Howard S ^a   Rote, William E ^a,b   Vlasuk, George P ^a,b   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DOG; DRUG EFFICACY; HOOKWORM; MOLECULAR CLONING; NEMATODE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; THROMBOSIS;

AMINO ACID SEQUENCE; ANCYLOSTOMA; ANIMALS; ANTICOAGULANTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HELMINTH PROTEINS; HEPARIN, LOW-MOLECULAR-WEIGHT; INJECTIONS, SUBCUTANEOUS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 0030856003     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. BARRADELL, L. B., BUCKLEY, M. M.: Nadroparin calcium: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 44: 858-888, 1992.
2. CAPPELLO, M., VLASUK, G. P., BERGUM, P. W., HUANG, S. AND HOTEZ, P. J.: Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa. Proc. Natl. Acad. Sci. U.S.A. 92: 6152-6156, 1995.
3. CHEN, L. Y., NICHOLS, W. W., HENDRICKS, J., MEHTA, J. L.: Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis. Am. Heart J. 129: 211-218, 1995.
4. DUNWIDDIE, C. T., THORNBERRY, N. A., BULL, H. G., SARDANA, M., FRIEDMAN, P. A., JACOBS, J. W. AND SIMPSON, E.: Antistasin: A leech-derived inhibitor of factor Xa, kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem. 264: 16694-16699, 1989.
5. DUNWIDDIE, C. T., NUTT, E. M., VLASUK, G. P., SIEGL, P. K. AND SCHAFFER, L. W.: Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor Antistasin following subcutaneous administration in the rhesus monkey. Thromb. Haemost. 67: 371-376, 1992.
6. FIORAVANTI, C., BURKHOLDER, D., FRANCIS, B., SIEGL, P. K. S. AND GIBSON, R. E.: Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb. Res. 71: 317-324, 1993.
7. FRAMPTON, J. E. AND FAULDS, D.: Parnaparin: A review of its pharmacology, and clinical applications in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 47: 652-676, 1994.
8. FRIEDEL, H. A. AND BALFOUR, J. A.: Tinzaparin: A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 48: 638-660, 1994.
9. GREEN, D., HIRSH, J., HEIT, J., PRINS, M., DAVIDSON, B. AND LENSING, A. W.: Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Revs. 46: 89-109, 1994.
10. JORDAN, R. E., FAVREAU, L. V., BRASWELL, E. H. AND ROSENBERG, R. D.: Heparin with two binding sites for antithrombin or platelet factor 4. J. Biol. Chem. 257: 400-406, 1982.
11. KANE, W. H. AND DAVIE, E. W.: Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71: 539-555, 1988.
12. LANE, D. A., DENTON, J., FLYNN, A. M., THUNBERG, L. AND LINDAHL, U.: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem. J. 218: 725-732, 1984.
13. LEFKOVITS, J., MALYCKY, J. L., RAO, S., HART, C. E., PLOW, E. F., TOPOL, E. J. AND NICOLINI, F. A.: Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. 28: 1858-1865, 1996.
14. LINDHOUT, T., BLEZER, R. AND HEMKER, C. H.: The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb. Haemost. 64: 464-468, 1990.
15. LYNCH, J. L., SITKO, G. R., LEHMAN, D. E. AND VLASUK, G. P.: Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb. Haemost. 74: 640-645, 1995.
16. MICKELSON, J. K., SIMPSON, P. J. AND LUCCHESI, B. R.: Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor comptex prevents coronary artery thrombosis in the canine heart. J. Mol. Cell Cardiol. 21: 393-405, 1989.
17. NEEPER, M. P., WAXMAN, L., SMITH, D. E., SCHULMAN, C. A., SARDANA, M., ELLIS, R. W., SCHAFFER, L. W., SIEGL, P. K. S. AND VLASUK, G. P.: Characterization of recombinant tick anticoagulant peptide (TAP): A highly selective inhibitor of blood coagulation factor Xa. J. Biol. Chem. 265: 17746-17752, 1990.
18. NICOLINI, F. A., LEE, P., MALYCKY, J. L., LEFKOVITS, J., KOTTKE-MARCHANT, K., PLOW, E. F. AND TOPOL, E. J.: Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul. Fibrinolysis 7: 39-48, 1996.
19. NUTT E., GASIC, T., RODKEY, J., GASIC, G. J., JACOBS, J. W., FRIEDMAN, P. A. AND SIMPSON, E.: Amino acid sequence of antistasin. J. Biol. Chem. 263: 10162-10167, 1988.
20. REBELLO, S. S., MILLER, B. V., BASLER, G. C. AND LUCCHESI, B. R.: CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J. Cardiovas. Pharmacol. 29: 240-249, 1997.
21. ROMSON, J. L., HAACK, D. W. AND LUCCHESI, B. R.: Electrical induction of coronary artery thrombosis in the ambulatory canine: A model for in vivo evaluation of antithrombotic agents. Thromb. Res. 17: 841-853, 1980.
22. ROTE, W. E. AND VLASUK, G. P.: Evaluation of a novel small protein inhibitor of blood coagulation factor Xa in a porcine model of acute coronary artery thrombosis. Circulation 92: suppl. 1, 2322, 1995.
23. SCHAFFER, L. W., DAVIDSON, J. T., VLASUK, G. P. AND SIEGEL, P. K. S.: Antithrombotic efficacy of recombinant tick anticoagulant peptide, a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 84: 1741-1748, 1991.
24. SCHAFFER, L. W., DAVIDSON, J. T., VLASUK, G. P., DUNWIDDIE, C. T. AND SIEGL, P. K. S.: Selective factor Xa inhibition by recombinant Antistasin prevents vascular graft thrombosis in baboons. Arterioscler. Thromb. 12: 879-885, 1992.
25. SHEBUSKI, R. J., STABILITO, I. J., SITKO, G. R. AND POLOKOFF, M. H.: Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 82: 169-77, 1990.
26. SITKO, G. R., RAMJIT, D. R., STABILITO, I. I., LEHMAN, D., LYNCH, J. L. AND VLASUK, G. P.: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 85: 805-815, 1992.
27. STANSSENS, P., BERGUM, P. W., GANSEMANS, Y., JESPERS, L., LAROCHE, Y., HUANG, S., MAKI, S., MESSENS, J., LAUWEREYS, M., CAPPELLO, M., HOTEZ, P. J., LASTERS, I. AND VLASUK, G. P.: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. Sci. U.S.A. 93: 2149-2154, 1996.
28. SUDO, Y., KILGORE, K. S. AND LUCCHESI, B. R.: Monoclonal antibody [7E3 F(ab′)2] prevents arterial but not venous rethrombosis. J. Cardiovasc. Pharmacol. 26: 241-250, 1995.
29. TEITEL, S. M. AND ROSENBERG, R. D.: Protection of factor Xa from neutralization by the heparin antithrombin-III complex. J. Clin. Invest. 71: 1383-1391, 1983.
30. TUSZYNSKI, G. P., GASIC, T. B. AND GASIC, G. J.: Isolation and characterization of Antistasin. J. Biol. Chem. 262: 9718-9723, 1987.
31. VLASUK, G. P., RAMJIT, D., FIJITA, T., DUNWIDDIE, C. T., NUTT, E. M., SMITH, D. E. AND SHEBUSKI, R. J.: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors Antistasin and tick anticoagulant peptide in a rabbit model of venous thrombosis. Thromb. Haemost. 65: 257-262, 1991.
32. VLASUK, G. P., DEMPSEY, E. M., OLDESCHULTE, G. L., BERNARDINO, V., RICHARD, B. M. AND ROTE, W. E.: Evaluation of a novel small protein inhibitor of blood coagulation factor Xa (rNAP5) in animal models of thrombosis. Circulation 92: suppl. 1, 3287, 1995.
33. WAXMAN, L., SMITH, D. E., ARCURI, K. E. AND VLASUK, G. P.: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248: 593-596, 1990.
34. WEITZ, J. I., HUDOBA, M., MASSEL, D., MARAGANORE, J. AND HIRSH, J.: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J. Clin. Invest. 86: 385-391, 1990.